(Q30660667)

English

Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 June 2017

Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine (English)

1 reference

Europe PubMed Central

26 June 2017

author name string

H Kovárová

1

1 reference

Europe PubMed Central

26 June 2017

M Hajdúch

2

1 reference

Europe PubMed Central

26 June 2017

G Korínková

3

1 reference

Europe PubMed Central

26 June 2017

P Halada

4

1 reference

Europe PubMed Central

26 June 2017

S Krupicková

5

1 reference

Europe PubMed Central

26 June 2017

A Gouldsworthy

6

1 reference

Europe PubMed Central

26 June 2017

N Zhelev

7

1 reference

Europe PubMed Central

26 June 2017

M Strnad

8

1 reference

Europe PubMed Central

26 June 2017

publication date

1 November 2000

1 reference

Europe PubMed Central

26 June 2017

Electrophoresis

1 reference

Europe PubMed Central

26 June 2017

21

1 reference

Europe PubMed Central

26 June 2017

17

1 reference

Europe PubMed Central

26 June 2017

3757-3764

1 reference

Europe PubMed Central

26 June 2017

Cancer cell cycles

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

New functional activities for the p21 family of CDK inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Cell-cycle dysregulation and the molecular mechanisms of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

High prevalence of p16 genetic alterations in head and neck tumours

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Inhibition of cyclin-dependent kinases by purine analogues.

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Human liver protein map: a reference database established by microsequencing and gel comparison

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Probability-based protein identification by searching sequence databases using mass spectrometry data

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Crystal structure of recombinant human triosephosphate isomerase at 2.8 A resolution. Triosephosphate isomerase-related human genetic disorders and comparison with the trypanosomal enzyme

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Identification of two human Rho GDP dissociation inhibitor proteins whose overexpression leads to disruption of the actin cytoskeleton

1 reference

https://api.crossref.org/works/10.1002%2F1522-2683%28200011%2921%3A17%3C3757%3A%3AAID-ELPS3757%3E3.0.CO%3B2-X

21 January 2018

Identifiers

10.1002/1522-2683(200011)21:17<3757::AID-ELPS3757>3.0.CO;2-X

1 reference

Europe PubMed Central

26 June 2017

1 reference

Europe PubMed Central

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30660667&oldid=1548058786"